$1.49 Billion is the total value of Rock Springs Capital Management LP's 133 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
UNH | New | UNITEDHEALTH GROUP INC | $26,407,000 | – | 165,000 | +100.0% | 1.77% | – |
RARX | New | RA PHARMACEUTICALS INC | $12,547,000 | – | 826,000 | +100.0% | 0.84% | – |
EVHC | New | ENVISION HEALTHCARE CORP | $9,177,000 | – | 145,000 | +100.0% | 0.61% | – |
ZBH | New | ZIMMER BIOMET HLDGS INC | $2,178,000 | – | 21,100 | +100.0% | 0.15% | – |
HQY | New | HEALTHEQUITY INC | $2,026,000 | – | 50,000 | +100.0% | 0.14% | – |
New | THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,713,000 | – | 1,500,000 | +100.0% | 0.12% | – | |
MYOV | New | MYOVANT SCIENCES LTD | $1,115,000 | – | 89,600 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
INVITAE CORP | 35 | Q3 2023 | 1.8% |
BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
MACROGENICS INC | 35 | Q3 2023 | 0.5% |
COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-01 |
SC 13G/A | 2024-04-05 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.